Albany Molecular (AMRI) Posts Q2 adj.-EPS of $0.06, Tops Views; Guides Q3 and FY10

Albany Molecular Research, Inc. (Nasdaq: AMRI) reports Q2 adjusted EPS of $0.06, 10 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $49.5 million, which compares to the estimate of $48.71 million. Sees Q3 revs of $43 - $46 million and a loss of ($0.11) - ($0.08). Consensus sees revs of $55.66 million and a loss...

Read More